These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16424035)

  • 1. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.
    Hoeflich KP; Gray DC; Eby MT; Tien JY; Wong L; Bower J; Gogineni A; Zha J; Cole MJ; Stern HM; Murray LJ; Davis DP; Seshagiri S
    Cancer Res; 2006 Jan; 66(2):999-1006. PubMed ID: 16424035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inducible BRAF suppression models for melanoma tumorigenesis.
    Hoeflich KP; Jaiswal B; Davis DP; Seshagiri S
    Methods Enzymol; 2008; 439():25-38. PubMed ID: 18374154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
    J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF is a therapeutic target in aggressive thyroid carcinoma.
    Salvatore G; De Falco V; Salerno P; Nappi TC; Pepe S; Troncone G; Carlomagno F; Melillo RM; Wilhelm SM; Santoro M
    Clin Cancer Res; 2006 Mar; 12(5):1623-9. PubMed ID: 16533790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.
    King AJ; Patrick DR; Batorsky RS; Ho ML; Do HT; Zhang SY; Kumar R; Rusnak DW; Takle AK; Wilson DM; Hugger E; Wang L; Karreth F; Lougheed JC; Lee J; Chau D; Stout TJ; May EW; Rominger CM; Schaber MD; Luo L; Lakdawala AS; Adams JL; Contractor RG; Smalley KS; Herlyn M; Morrissey MM; Tuveson DA; Huang PS
    Cancer Res; 2006 Dec; 66(23):11100-5. PubMed ID: 17145850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.
    Sala E; Mologni L; Truffa S; Gaetano C; Bollag GE; Gambacorti-Passerini C
    Mol Cancer Res; 2008 May; 6(5):751-9. PubMed ID: 18458053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis.
    Zhao Y; Zhang Y; Yang Z; Li A; Dong J
    Biochem Biophys Res Commun; 2008 Jun; 370(3):509-13. PubMed ID: 18402768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
    Kumar SM; Yu H; Edwards R; Chen L; Kazianis S; Brafford P; Acs G; Herlyn M; Xu X
    Cancer Res; 2007 Apr; 67(7):3177-84. PubMed ID: 17409425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
    Tanami H; Imoto I; Hirasawa A; Yuki Y; Sonoda I; Inoue J; Yasui K; Misawa-Furihata A; Kawakami Y; Inazawa J
    Oncogene; 2004 Nov; 23(54):8796-804. PubMed ID: 15467732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Narrative review: BRAF opens the door for therapeutic advances in melanoma.
    Flaherty KT
    Ann Intern Med; 2010 Nov; 153(9):587-91. PubMed ID: 21041578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of ERK3/MAPK6 expression by BRAF.
    Hoeflich KP; Eby MT; Forrest WF; Gray DC; Tien JY; Stern HM; Murray LJ; Davis DP; Modrusan Z; Seshagiri S
    Int J Oncol; 2006 Oct; 29(4):839-49. PubMed ID: 16964379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Models and mechanisms in malignant melanoma.
    Benjamin CL; Melnikova VO; Ananthaswamy HN
    Mol Carcinog; 2007 Aug; 46(8):671-8. PubMed ID: 17570501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells.
    Smith AG; Lim W; Pearen M; Muscat GE; Sturm RA
    Pigment Cell Melanoma Res; 2011 Jun; 24(3):551-63. PubMed ID: 21362156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of BRAF(V599E) in human melanoma abrogates transformation.
    Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA
    Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RKIP downregulates B-Raf kinase activity in melanoma cancer cells.
    Park S; Yeung ML; Beach S; Shields JM; Yeung KC
    Oncogene; 2005 May; 24(21):3535-40. PubMed ID: 15782137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.
    Dong J; Phelps RG; Qiao R; Yao S; Benard O; Ronai Z; Aaronson SA
    Cancer Res; 2003 Jul; 63(14):3883-5. PubMed ID: 12873977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells.
    Sumimoto H; Imabayashi F; Iwata T; Kawakami Y
    J Exp Med; 2006 Jul; 203(7):1651-6. PubMed ID: 16801397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF kinase in melanoma development and progression.
    DeLuca AM; Srinivas A; Alani RM
    Expert Rev Mol Med; 2008 Feb; 10():e6. PubMed ID: 18279546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.